Type 2 Diabetes Mellitus
Conditions
Interventions
None listed
Sponsors
Sapporo Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion Criteria (Patients who meet all of the following conditions at the time of informed consent will be eligible for the study.) 1. Patients with type 2 diabetes mellitus 2. Patients who are scheduled to receive tofogliflozin 3. Patients aged 18 years or older at the time of informed consent
Exclusion criteria
Exclusion criteria: Exclusion Criteria (Patients who meet any of the following conditions at the time of informed consent will be excluded from the study.) 1. Patients with a history of hypersensitivity to any component of tofogliflozin 2. Patients with severe ketosis, diabetic coma, or precoma 3. Patients with severe infections, undergoing surgery or in the perioperative period, or with serious trauma 4. Patients who have newly initiated or changed the dosage or administration of antidiabetic medication within 12 weeks prior to informed consent 5. Patients with chronic kidney disease (CKD) stage 4 or 5 6. Pregnant or lactating women, or women who intend to become pregnant 7. Patients deemed inappropriate for inclusion in the study by the attending physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change (amount and rate) in blood amino acid concentration from baseline at 48 weeks of administration | — |
Countries
Japan
Contacts
Public ContactToshiyuki Yano
Sapporo Medical University Department of Cardiovascular, Renal and Metabolic Medicine
Outcome results
None listed